Active Recombinant Human CTF1 protein(Ser2-Ala201)

• Cat.No.: CTF1-238H
• Product Overview: Recombinant Human CTF1 (NP_001321.1) (Ser2-Ala201) was expressed in HEK293 with two additional amino acids (Gly & Pro) at the N-terminus.

Specification

• Species: Human
• Source: HEK293
• Tag: Non
• Protein Length: Ser2-Ala201
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 2-10 ng/ml.
• Molecular Mass: The recombinant human CTF1 comprises 202 amino acids and has a predicted molecular mass of 21.2 kDa. The apparent molecular mass of the protein is approximately 26.6 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 85 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CTF1 cardiotrophin 1 [ Homo sapiens ]
• Official Symbol: CTF1
• Synonyms: CTF1; cardiotrophin 1; cardiotrophin-1; CT 1; CT1; cardiophin 1; CT-1
• Gene ID: 1489
• mRNA Refseq: NM_001142544
• Protein Refseq: NP_001136016
• MIM: 600435
• UniProt ID: Q16619

Case Study

Case 1: Ping Y, et al. J Clin Lab Anal. 2021

This study develops a rapid, sensitive one-step MPs-CLIA method for detecting cardiotrophin-1 (CT-1), a key heart failure biomarker, using streptavidin-modified paramagnetic particles and biotin/acridinium ester-labeled antibodies. The assay demonstrates high sensitivity (1.0 pg/mL detection limit), wide linearity (7.8 pg/mL–200 ng/mL), and reliable precision (recoveries 96–110%; intra-/inter-assay CVs ≤10.9%), validated through 140 clinical samples. This chemiluminescence immunoassay shows strong potential for heart failure diagnosis and prognosis assessment.

Fig1. Calibration curve for the determination of CT-1 by MPs-CLIA.

Fig2. Correlation between plasma levels of CT-1 and pro-BNP in 44 CHF patients.

Case 2: Abdul-Ghani M, et al. Cell Res. 2017

This study reveals cardiotrophin-1 (CT-1) drives physiological cardiac hypertrophy by enhancing myocardial angiogenesis via CK2-mediated caspase regulation, distinguishing it from pathological growth. Using a heart failure model, CT-1 protein therapy reversed pathology and restored cardiac function, demonstrating potential for right heart failure treatment. Findings highlight CT-1's dual role in adaptive cardiac remodeling and its therapeutic value in heart disease management.

Fig1. Human cardiotrophin 1 (hCT1) induces morphologic changes in primary cardiomyocytes.

Fig2. hCT1 treatment significantly decreased cardiomyocyte cross-sectional area.

Application

1. Therapeutic Potential of Recombinant CT1 Protein in Cardiovascular Disease Recombinant CT1 protein emerges as a promising therapeutic agent for cardiovascular disorders, particularly heart failure. Studies demonstrate its ability to induce physiological cardiac hypertrophy—a reversible, adaptive myocardial enlargement—by stimulating cardiomyocyte-derived angiogenic signals, enhancing vascularization without pathological remodeling. This process is regulated via the CK2 signaling pathway, which suppresses caspase activation, preventing detrimental cardiac fibrosis. 2. Mechanistic Insights and Clinical Applications In preclinical models of right ventricular dysfunction, recombinant CT1 administration restored contractile function and reduced fibrosis, highlighting its potential for heart failure therapy. Its angiogenic properties also support applications in regenerative medicine, particularly for ischemic heart disease, where improved vascularization can mitigate tissue damage. 3. Diagnostic and Prognostic Utility Beyond therapy, plasma CT1 levels are being explored as cardiovascular biomarkers to track heart failure progression and recovery. Ongoing research focuses on optimizing dosing protocols and evaluating long-term safety, positioning recombinant CT1 as a dual-purpose tool for both treatment and monitoring.

Fig1. Proposed model of hCT1-mediated physiologic cardiac hypertrophy. (Mohammad Abdul-Ghani, 2017)